BSE Pharma Sector Regulatory Filings — July 23, 2026

23-07-2026

Cipla Limited has informed the stock exchanges that the audio recording of its earnings conference call for the quarter ended June 30, 2026, held on July 23, 2026, is now available on the company's website. This is a routine regulatory disclosure under SEBI Listing Regulations and does not contain any financial results or performance data.

23-07-2026

Cipla reported Q1 FY27 consolidated revenue of INR 7,119 Cr, up 2% YoY from INR 6,957 Cr, with One-India delivering its highest-ever quarterly sales (INR 3,452 Cr, +12% YoY). However, EBITDA fell sharply to INR 1,192 Cr (16.7% margin) from INR 1,778 Cr (25.6% margin) and PAT declined to INR 789 Cr from INR 1,298 Cr, driven by a 21% drop in North America revenue (INR 1,532 Cr vs INR 1,933 Cr) and a 28% fall in API and Others (INR 160 Cr vs INR 222 Cr).

• · EBITDA margin contracted to 16.7% from 25.6% YoY.
• · North America revenue declined 21% YoY to INR 1,532 Cr ($162 Mn).
• · South Africa revenue fell 5% YoY to INR 658 Cr.
• · API and Others revenue dropped 28% YoY to INR 160 Cr.
• · R&D spend increased 12.3% YoY to INR 486 Cr (6.8% of sales).
• · Net cash position stood at INR 9,494 Cr; total debt was INR 600 Cr.
• · Albuterol ranked No.1 in US Albuterol MDI market with 21% share.
• · Chronic mix in One-India improved to 60.4%.
• · Branded Prescription grew 15.4% (183 bps above IPM).
• · Trade Generics launched 3 new products during the quarter.
• · Consumer Health anchor brands (Nicotex, Omnigel, Cipladine) maintained leadership.
• · South Africa private market secondary growth was 6.5% vs market 5.7%.
• · Emerging Markets and Europe grew 5% YoY in USD terms.
• · Earnings conference call scheduled for July 23, 2026 at 1600 hrs IST.

23-07-2026

23-07-2026

Cipla Limited reported its highest-ever Q1 revenue of INR 7,119 Cr for Q1FY27, driven by strong performance in the One India segment (INR 3,452 Cr, +12% YoY) and the launch of gVentolin in North America. However, EBITDA margin declined sharply to 16.7% from 25.6% in Q1FY26, and PAT fell to INR 789 Cr from INR 1,298 Cr YoY, reflecting higher costs and investments. The North America revenue was $162 Mn, while One Africa grew 5% to $106 Mn.

• · One India revenue of INR 3,452 Cr was the highest ever for a Q1, with chronic mix improving to 60.4%.
• · North America revenue was $162 Mn, with gProventil maintaining #1 market share at 21% in the U.S. Albuterol MDI market.
• · Emerging Markets & Europe revenue was $103 Mn, showing only 1% YoY growth (flat).
• · One Africa revenue grew 5% YoY to $106 Mn, with South Africa private business growing faster than the market (9.8% vs 6.9% for prescription).
• · R&D spend was INR 486 Cr, representing 6.8% of revenue.
• · Total debt increased to INR 600 Cr from INR 459 Cr, while cash and equivalents decreased to INR 10,094 Cr from INR 10,838 Cr.
• · Goodwill and intangibles rose sharply to INR 6,928 Cr from INR 5,138 Cr, a 34.8% increase.
• · ESG progress: renewable electricity share at 57% (target 80% by FY30), GHG reduction at 21% (target 30%), water positivity achieved at 2.6x, zero waste to landfill certification expected Mar'27.
• · Women representation in leadership group at 14.8%, targeting 20% by FY25 baseline.
• · Cipla Medpro Manufacturing in South Africa achieved GBCSA Net Zero Waste Certification.

23-07-2026

Cipla Limited announced a CFO transition effective July 23-24, 2026. Mr. Ashish Adukia has stepped down as Global CFO and KMP to move into an internal business leadership role, and Mr. Dinesh Jain, previously Head of Corporate Finance, has been appointed as the new Global CFO and KMP. The change is a routine leadership succession with no financial impact disclosed.

• · The board meeting started at 9:15 a.m. IST and concluded at 1:00 p.m. IST on July 23, 2026.
• · Mr. Dinesh Jain is a qualified Chartered Accountant and member of the Institute of Chartered Accountants of India with over three decades of experience.
• · Mr. Jain has led merger, amalgamation, and corporate restructuring initiatives at Cipla.

23-07-2026

Cipla Limited announced a CFO transition effective July 23, 2026: Mr. Ashish Adukia stepped down as Global CFO and KMP to move into an internal business leadership role, and Mr. Dinesh Jain, previously Head of Corporate Finance, was appointed as the new Global CFO and KMP effective July 24, 2026. The change was approved at a Board meeting held on the same day.

• · The Board meeting started at 9:15 a.m. IST and concluded at 1:00 p.m. IST on July 23, 2026.
• · Mr. Dinesh Jain is a qualified Chartered Accountant and member of ICAI with over three decades of experience in strategic planning, corporate finance, M&A, and restructuring.
• · The transition is part of a move by Mr. Adukia to an internal business leadership role, not a resignation from the company.

23-07-2026

Cipla Limited has granted 5,530 stock options under ESOS 2013-A and 19,179 Employee Stock Appreciation Rights (ESARs) under ESAR 2021 to employees. The stock options have a 2-year vesting period from the grant date, while ESARs have a 3-year graded vesting, both with a 5-year exercise period from vesting. The exercise price is INR 2 per option/equity share.

• · The Board meeting commenced at 9:15 a.m. IST and concluded at 1:00 p.m. IST on July 23, 2026.
• · The grants are made under SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.